Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jazz Pharmaceuticals plc Director's Dealing 2026

Jan 21, 2026

30751_dirs_2026-01-21_5e2e849a-e076-421d-980e-031721a6874d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2026-01-16

Reporting Person: COZADD BRUCE C (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2026-01-16 Ordinary Shares A 35917 $0.0 Acquired 429249 Direct
2026-01-16 Ordinary Shares F 17453 $171.16 Disposed 411796 Direct

Footnotes

F1: Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance
attained was certified.

F2: Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations.